Overview of This Study:

This research employed a large number of primary and secondary sources. In order to determine the segmentation types, industry trends, major players, competitive landscape, important market dynamics, and major player strategies, the research process involved analyzing a variety of industry-affecting factors.

Global Growth Driving Factors:

The market for ATP assays is primarily driven by factors like the expansion of drug discovery and development studies, the increasing penetration of CROs, the growing need for cell-based assays in research, and the expansion of investments made by pharmaceutical and biotechnology companies.

Revenue Growth Expectations:

With a predicted revenue of $0.3 billion in 2023 and a projected growth rate of 7.8% from 2023 to 2028, the global ATP assays market is expected to reach $0.5 billion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223438780

OPPORTUNITY: Advancements in technology for ATP assay probes

In both unicellular and multicellular organisms, ATP functions as a universal mediator of metabolism and signaling. The dynamics of ATP and the physiology that develops at the intracellular and extracellular levels are fundamentally interdependent. Characterizing and understanding ATP dynamics, therefore, provides important mechanistic insights into a variety of processes, ranging from immune cell chemotaxis to neurotransmission. Thus, a methodology to investigate the temporal and spatial aspects of ATP dynamics in living specimens—from the subcellular to the organismal levels—is necessary. Many molecular probes specific to ATP have been developed over the last few decades. These probes have made it possible to detect this important molecule both qualitatively and quantitatively by combining them with imaging techniques, primarily optical microscopy.

End Users:

The pharmaceutical & biotechnology segment accounted for the largest share of the market in 2022

The pharmaceutical and biotechnology industries, the food and beverage sector, hospitals and diagnostic labs, and academic and research institutes make up the end-user segments of the ATP assays market. There are a few main reasons for this segment's dominance. The increasing number of pharmaceutical companies investing heavily in this market, the growing regulatory approvals for vaccines based on cell culture that require the use of ATP assays for contamination testing, the expansion of pharmaceutical companies' commercial activities, the growing need for gene and cell therapies to treat chronic illnesses, and the substantial research and development efforts in the pharmaceutical and biopharmaceutical sectors are some of these factors.

Geographical Growth Scenario:

The ATP assays market in North America is expected to grow significantly between 2023 and 2028.

The ATP Assays market is split into the following regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is anticipated to hold the largest market share in the ATP Assays market in 2023. This is explained by the application of cutting-edge technologies in microbiological detection, the increase in the need for cell-based assays in research, and the availability of first-rate facilities for laboratory and clinical research, all of which are fostering market expansion.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=223438780

Key Players:

The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Abcam plc (UK), Lonza Group (Switzerland), Neogen Corporation (US), 3M (US), Danaher Corporation (US), PromoCell GmbH (Germany), Geno Technology, Inc. (US), Abnova Corporation (Taiwan), AAT Bioquest,Inc. (US), BioThema AB (Sweden), Elabscience Biotechnology Inc. (US), MBL International Corporation (US), Biotium (US), Creative Bioarray (US), Canvax Biotech S.L. (Spain), Ruhof Corporation (US), Charm Sciences, Inc. (US), Bio Shield Tech, LLC (US), Cayman Chemical (US), and Cell Signaling Technology,Inc. (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]